Company Profile
Fortress Biotech Stock Price, News & Catalysts
- Ticker:
- FBIO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.77 USD (-2.81%)
Close
Last updated: August 20, 2026
88M USD
Market cap
Why the stock is moving
As of Aug 20, 2026, FBIO closed down 2.81% at $2.77. No new same-company headline was identified in the current news window.
Company overview
Multi-Asset Biopharmaceutical Holding Company
Fortress Biotech creates value by acquiring, forming, and advancing biopharmaceutical businesses and assets. Its portfolio includes commercial prescription products, development-stage programs, controlled subsidiaries, and minority investments across oncology, dermatology, and rare diseases.
Decentralized Company-Building Model
Fortress frequently places individual assets within focused subsidiaries that can raise capital, form partnerships, or pursue strategic transactions independently. The parent company retains value through equity ownership, royalties, milestones, and other contractual economics.
Rare Disease and Commercial Assets
Subsidiary Cyprium obtained FDA approval for ZYCUBO in Menkes disease and monetized the associated Rare Pediatric Disease Priority Review Voucher. Following Sun Pharma’s acquisition of Checkpoint, Fortress retains long-term royalty exposure to UNLOXCYT.
Multiple Monetization Pathways
Fortress can realize value through commercial product revenue, subsidiary transactions, priority review vouchers, royalties, milestone payments, and retained equity interests. This structure means portfolio value may be created through regulatory success or strategic transactions at individual subsidiaries.
Partnership-Sourced Pipeline
Fortress sources programs through collaborations with organizations including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber, and Sentynl. Avenue’s acquisition of ATX-04 from Duke University adds a clinically validated program in Pompe disease.
Future catalysts
- Triplex clinical data in patients co-infected with HIV and cytomegalovirus by the end of 2026.
- Initiation of the MB-109 study in recurrent glioblastoma and high-grade astrocytoma in the fourth quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Fortress Biotech (FBIO)?
Fortress Biotech (FBIO) most recently closed at 2.77 USD, a -2.81% move versus the previous session.
What is the market cap of Fortress Biotech (FBIO)?
Fortress Biotech currently has a market capitalization of 88M USD on BioPharmSignal.
What does Fortress Biotech do?
Multi-Asset Biopharmaceutical Holding Company Fortress Biotech creates value by acquiring, forming, and advancing biopharmaceutical businesses and assets. Its portfolio includes commercial prescription products, development-stage programs, controlled subsidiaries, and minority investments across oncology, dermatology, and rare diseases. Decentralized...
On which exchange is FBIO stock listed?
Fortress Biotech (FBIO) is associated with NASDAQ, United States, Biopharma.
What is ATX-04?
Avenue’s acquisition of ATX-04 from Duke University adds a clinically validated program in Pompe disease.
Which conditions is Fortress Biotech targeting with ATX-04?
Fortress Biotech is associated with oncology, rare disease, dermatology based on its company overview and current catalyst commentary.
How does Fortress Biotech describe recent progress with ATX-04?
Triplex clinical data in patients co-infected with HIV and cytomegalovirus by the end of 2026. Initiation of the MB-109 study in recurrent glioblastoma and high-grade astrocytoma in the fourth quarter of 2026.
What is MB-109?
Initiation of the MB-109 study in recurrent glioblastoma and high-grade astrocytoma in the fourth quarter of 2026.